Abstract
Patients with genital herpes were treated three times weekly for 12 weeks with 3 X 10(6) IU of alpha 2b interferon (20 patients) or placebo (17 patients) administered by subcutaneous injection in a double-blind trial. Interferon had minimal effects on the suppression of recurrences and moderate toxicity (chills, fever, fatigue, and leukopenia), suggesting that this route and dosage of interferon may not be clinically useful for this indication.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Corey L., Adams H. G., Brown Z. A., Holmes K. K. Genital herpes simplex virus infections: clinical manifestations, course, and complications. Ann Intern Med. 1983 Jun;98(6):958–972. doi: 10.7326/0003-4819-98-6-958. [DOI] [PubMed] [Google Scholar]
- Douglas J. M., Critchlow C., Benedetti J., Mertz G. J., Connor J. D., Hintz M. A., Fahnlander A., Remington M., Winter C., Corey L. A double-blind study of oral acyclovir for suppression of recurrences of genital herpes simplex virus infection. N Engl J Med. 1984 Jun 14;310(24):1551–1556. doi: 10.1056/NEJM198406143102402. [DOI] [PubMed] [Google Scholar]
- Farr B. M., Gwaltney J. M., Jr, Adams K. F., Hayden F. G. Intranasal interferon-alpha 2 for prevention of natural rhinovirus colds. Antimicrob Agents Chemother. 1984 Jul;26(1):31–34. doi: 10.1128/aac.26.1.31. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Fraser-Smith E. B., Eppstein D. A., Marsh Y. V., Matthews T. R. Enhanced efficacy of the acyclic nucleoside 9-(1,3-dihydroxy-2-propoxymethyl)guanine in combination with beta-interferon against herpes simplex virus type 2 in mice. Antimicrob Agents Chemother. 1984 May;25(5):563–565. doi: 10.1128/aac.25.5.563. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Hirsch M. S., Schooley R. T., Cosimi A. B., Russell P. S., Delmonico F. L., Tolkoff-Rubin N. E., Herrin J. T., Cantell K., Farrell M. L., Rota T. R. Effects of interferon-alpha on cytomegalovirus reactivation syndromes in renal-transplant recipients. N Engl J Med. 1983 Jun 23;308(25):1489–1493. doi: 10.1056/NEJM198306233082501. [DOI] [PubMed] [Google Scholar]
- Ho M., Pazin G. J., Armstrong J. A., Haverkos H. S., Dummer J. S., Jannetta P. J. Paradoxical effects of interferon on reactivation of oral infection with herpes simplex virus after microvascular decompression for trigeminal neuralgia. J Infect Dis. 1984 Dec;150(6):867–872. doi: 10.1093/infdis/150.6.867. [DOI] [PubMed] [Google Scholar]
- Moran D. M., Kern E. R., Overall J. C., Jr Synergism between recombinant human interferon and nucleoside antiviral agents against herpes simplex virus: examination with an automated microtiter plate assay. J Infect Dis. 1985 Jun;151(6):1116–1122. doi: 10.1093/infdis/151.6.1116. [DOI] [PubMed] [Google Scholar]
- Pazin G. J., Armstrong J. A., Lam M. T., Tarr G. C., Jannetta P. J., Ho M. Prevention of reactivated herpes simplex infection by human leukocyte interferon after operation on the trigeminal root. N Engl J Med. 1979 Aug 2;301(5):225–230. doi: 10.1056/NEJM197908023010501. [DOI] [PubMed] [Google Scholar]
- Stiehm E. R., Kronenberg L. H., Rosenblatt H. M., Bryson Y., Merigan T. C. UCLA conference. Interferon: immunobiology and clinical significance. Ann Intern Med. 1982 Jan;96(1):80–93. doi: 10.7326/0003-4819-96-1-80. [DOI] [PubMed] [Google Scholar]
- Straus S. E., Takiff H. E., Seidlin M., Bachrach S., Lininger L., DiGiovanna J. J., Western K. A., Smith H. A., Lehrman S. N., Creagh-Kirk T. Suppression of frequently recurring genital herpes. A placebo-controlled double-blind trial of oral acyclovir. N Engl J Med. 1984 Jun 14;310(24):1545–1550. doi: 10.1056/NEJM198406143102401. [DOI] [PubMed] [Google Scholar]